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Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the
treatment of myeloma and carries less risk of peripheral neuropathy than first-generation
proteasome inhibitors, making it more amenable to combination therapy.
Methods and findings
The Myeloma XI+ trial recruited patients from 88 sites across the UK between 5 December
2013 and 20 April 2016. Patients with newly diagnosed multiple myeloma eligible for
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transplantation were randomly assigned to receive the combination carfilzomib, lenalido-
mide, dexamethasone, and cyclophosphamide (KRdc) or a triplet of lenalidomide, dexa-
methasone, and cyclophosphamide (Rdc) or thalidomide, dexamethasone, and
cyclophosphamide (Tdc). All patients were planned to receive an autologous stem cell
transplantation (ASCT) prior to a randomisation between lenalidomide maintenance and
observation. Eligible patients were aged over 18 years and had symptomatic myeloma. The
co-primary endpoints for the study were progression-free survival (PFS) and overall survival
(OS) for KRdc versus the Tdc/Rdc control group by intention to treat. PFS, response, and
safety outcomes are reported following a planned interim analysis. The trial is registered
(ISRCTN49407852) and has completed recruitment. In total, 1,056 patients (median age 61
years, range 33 to 75, 39.1% female) underwent induction randomisation to KRdc (n = 526)
or control (Tdc/Rdc, n = 530). After a median follow-up of 34.5 months, KRdc was associ-
ated with a significantly longer PFS than the triplet control group (hazard ratio 0.63, 95% CI
0.51–0.76). The median PFS for patients receiving KRdc is not yet estimable, versus 36.2
months for the triplet control group (p < 0.001). Improved PFS was consistent across sub-
groups of patients including those with genetically high-risk disease. At the end of induction,
the percentage of patients achieving at least a very good partial response was 82.3% in the
KRdc group versus 58.9% in the control group (odds ratio 4.35, 95% CI 3.19–5.94, p <
0.001). Minimal residual disease negativity (cutoff 4 × 10−5 bone marrow leucocytes) was
achieved in 55% of patients tested in the KRdc group at the end of induction, increasing to
75% of those tested after ASCT. The most common adverse events were haematological,
with a low incidence of cardiac events. The trial continues to follow up patients to the co-pri-
mary endpoint of OS and for planned long-term follow-up analysis. Limitations of the study
include a lack of blinding to treatment regimen and that the triplet control regimen did not
include a proteasome inhibitor for all patients, which would be considered a current standard
of care in many parts of the world.
Conclusions
The KRdc combination was well tolerated and was associated with both an increased per-
centage of patients achieving at least a very good partial response and a significant PFS




Why was this study done?
• Although outcomes for myeloma patients have improved over recent decades, many
patients will eventually relapse, and finding new treatment regimens that keep patients
in first remission for longer is imperative.
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• Treatment combinations aim to target myeloma using different mechanisms of action.
This aims to prevent resistant cells remaining and leading to relapse.
• Carfilzomib has been shown to be effective in the treatment of relapsed myeloma when
given in combination with lenalidomide.
• We performed this study to compare the outcomes of newly diagnosed myeloma
patients treated with the combination carfilzomib, lenalidomide, dexamethasone, and
cyclophosphamide (KRdc) to those of patients treated with immunomodulatory-agent-
based triplet control combinations.
What did the researchers do and find?
• A total of 1,056 patients with newly diagnosed myeloma were randomised between
KRdc and control.
• Patients receiving the quadruplet KRdc combination were more likely to achieve at least
a very good partial response and had longer progression-free survival than patients
receiving control treatments.
• Side effects were not significantly increased with the quadruplet combination compared
to control.
What do the findings mean?
• The results suggest that KRdc can elicit deep responses and long periods of progression-
free survival with tolerable side effects in newly diagnosed myeloma patients.
• Further studies are needed to compare KRdc to combinations of other new agents for
the treatment of newly diagnosed myeloma patients.
Introduction
Multiple myeloma is a malignancy of plasma cells that can lead to bone destruction, anaemia,
renal dysfunction, and/or hypercalcaemia. Outcomes for patients with myeloma have
improved considerably in the last few decades following the introduction of immunomodula-
tory agents and proteasome inhibitors, the use of autologous stem cell transplantation (ASCT),
and improvements in supportive care strategies. There is a strong rationale for delivering
induction treatment using combinations of agents with different mechanisms of action to
overcome intra-clonal heterogeneity [1,2]. However, the additional toxicities of combinations
of 3, 4, or more drugs can limit their clinical utility. Carfilzomib is a second-generation irre-
versible proteasome inhibitor that is structurally and mechanistically distinct from the first-
generation proteasome inhibitor, bortezomib [3]. Carfilzomib has been shown to be safe and
effective in relapsed multiple myeloma, both in a doublet combination with dexamethasone
(Kd) in the ENDEAVOR trial [4,5] and in triplets such carfilzomib, lenalidomide, and dexa-
methasone (KRd), evaluated in the ASPIRE trial [6,7]. The impressive results of these studies
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support the investigation of carfilzomib and lenalidomide given in combination for induction
treatment in newly diagnosed, transplant-eligible patients. We report the results of a planned
interim analysis of Myeloma XI+, a phase III randomised trial of the combination carfilzomib,
lenalidomide, dexamethasone, and cyclophosphamide (KRdc) in comparison to an immuno-
modulatory-agent-based triplet control for newly diagnosed multiple myeloma patients des-
tined for ASCT.
Methods
Study design and participants
The Myeloma XI+ trial is a multi-centre, randomised, open-label, phase III trial. This planned
interim analysis reports the first of 2 co-primary outcomes—progression-free survival (PFS)—
and secondary and safety outcomes. The study is closed for accrual, but follow-up continues
for planned long-term analysis. All authors contributed to the development of the manuscript,
approved the final version, and vouch for the accuracy and completeness of the data and for
the fidelity of the trial to the protocol. A completed CONSORT checklist is available (Text A in
S1 Text). The study is registered with the ISRCTN registry (ISRCTN49407852) and EU Clini-
cal Trials Register (2009-010956-93).
Eligible patients were recruited from 88 National Health Service sites across the UK
(Table A in S1 Text) between 5 December 2013 and 20 April 2016. These sites ranged from
academic medical centres to local district general hospitals. Inclusion criteria allowed the
enrolment of patients who were 18 years or older and had newly diagnosed symptomatic mye-
loma. Patients were excluded if they had previous or concurrent active malignancies (includ-
ing myelodysplastic syndrome), peripheral neuropathy of grade 2 or greater, acute renal
failure (characterised by creatinine > 500 μmol/l, urine output < 400 ml/day, or requirement
for dialysis and unresponsive to up to 72 hours of rehydration), or active or prior hepatitis C
virus infection. Further details regarding the inclusion and exclusion criteria can be found in
the protocol (Text B in S1 Text).
Myeloma XI+ followed the Myeloma XI trial using a seamless adaptation to implement a
novel treatment approach soon after it became available. Myeloma XI had pathways for both
transplant-eligible and -ineligible patients. Patients in the transplant-eligible pathway were
randomised between thalidomide, dexamethasone, and cyclophosphamide (Tdc) and lenalido-
mide, dexamethasone, and cyclophosphamide (Rdc), with subsequent response-adapted inten-
sification and maintenance randomisations that were also carried forward into Myeloma XI+.
Myeloma XI+ was only for transplant-eligible patients and was designed and opened before
Myeloma XI data had matured; as such, the primary outcome was the comparison between
KRdc and the triplet approaches studied in Myeloma XI and continued into Myeloma XI+.
Results of the Tdc versus Rdc randomisation in transplant-eligible patients from Myeloma XI
showed a small, but statistically significant improvement in PFS and overall survival (OS) asso-
ciated with receiving Rdc [8]; results of the cyclophosphamide, bortezomib, and dexametha-
sone (CVD) intensification randomisation and the maintenance randomisation are also
published [9,10]. This paper reports only patients contemporaneously randomised between
KRdc and Rdc/Tdc as per the statistical analysis plan for the study.
Randomisation and treatment
Patients were randomly assigned in a 2:1:1 ratio between KRdc, Rdc, and Tdc (Fig 1). All ran-
domisations were performed at the Clinical Trials Research Unit (Leeds, UK) using a central-
ised, automated 24-hour telephone system. Due to the nature of the intervention, patients and
their physicians were aware of the treatment allocation. A minimisation algorithm with a
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PFS, progression-free survival; PFS2, progression-
free survival 2; Rdc, lenalidomide, dexamethasone,
and cyclophosphamide; SAE, serious adverse
event; Tdc, thalidomide, dexamethasone, and
cyclophosphamide; VGPR, very good partial
response; VRd, bortezomib, lenalidomide, and
dexamethasone.
random element was used to avoid chance imbalances in 6 variables measured at trial entry: β2
microglobulin (<3.5 mg/l versus 3.5 to<5.5 mg/l versus�5.5 mg/l versus or unknown), hae-
moglobin (<115 g/l versus�115 g/l for men; <95 g/l versus�95 g/l for women), corrected
serum calcium (<2.6 mmol/l versus�2.6 mmol/l), serum creatinine (<140 μmol/l versus
�140 μmol/l), platelets (<150 × 109 cells/l versus�150 × 109 cells/l), and centre.
Initial induction treatment with KRdc, Rdc, or Tdc was administered, in the absence of tox-
icity, consent withdrawal, or progression, for a minimum of 4 cycles and to maximum
response. Patients in the KRdc group received 28-day cycles of carfilzomib 36 mg/m2 IV on
days 1, 2, 8, 9, 15, and 16 (20 mg/m2 on days 1 and 2); lenalidomide 25 mg PO on days 1–21;
dexamethasone 40 mg PO on days 1–4, 8, 9, 15, and 16; and cyclophosphamide 500 mg PO on
days 1 and 8. In cycle 1 intravenous hydration was recommended prior to administration of
carfilzomib with 250 to 500 ml of normal saline or other appropriate IV fluid. Carfilzomib was
dose capped at a body surface area of 2.2 m2. Investigators were advised to routinely evaluate
and treat hypertension and monitor patients for cardiac events.
Patients in the Rdc group received 28-day cycles of lenalidomide 25 mg PO on days 1–21;
dexamethasone 40 mg PO on days 1–4 and 12–15; and cyclophosphamide 500 mg PO on days
1 and 8. Patients in the Tdc group received 21-day cycles of thalidomide 100 mg (increasing to
200 mg as tolerated) PO on days 1–21; dexamethasone 40 mg PO on days 1–4 and 12–15; and
cyclophosphamide 500 mg PO on days 1, 8, and 15. Patients who received Tdc/Rdc underwent
response-adapted intensification, with those achieving only minimal or partial response
undergoing a randomisation to a proteasome inhibitor (bortezomib)–containing triplet
(CVD) or no further therapy. All patients who received Tdc/Rdc with stable or progressive dis-
ease received CVD. CVD was administered in 21-day cycles of cyclophosphamide 500 mg PO
Fig 1. Patient disposition. ASCT, autologous stem cell transplantation; CR, complete response; CVD, cyclophosphamide, bortezomib, and dexamethasone; KRdc,
carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; MR, minimal response; PD, progressive disease; PR, partial response; Rdc, lenalidomide,
dexamethasone, and cyclophosphamide; SD, stable disease; Tdc, thalidomide, dexamethasone, and cyclophosphamide; VGPR, very good partial response.
https://doi.org/10.1371/journal.pmed.1003454.g001
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on days 1 and 8; bortezomib 1.3 mg/m2 SC or IV on days 1, 4, 8, and 11; and dexamethasone
20 mg PO on days 1, 2, 4, 5, 8, 9, 11, and 12.
Peripheral blood stem cell harvest commenced after the patient had completed induction
therapy, followed by high-dose melphalan and stem cell return according to local practice but
with the intention to deliver melphalan 200 g/m2 (except 140 mg/m2 in those with renal insuf-
ficiency, defined as serum creatinine� 200 μmol/l prior to transplant). A maintenance rando-
misation at 3 months post-ASCT compared lenalidomide (10 mg PO on days 1–21 of a 28-day
cycle until disease progression) to observation.
Endpoints and assessments
The co-primary endpoints of the trial were PFS and OS. PFS was defined as the time from ran-
domisation to progressive disease or death from any cause. OS was defined as the time from
randomisation to death from any cause or last follow-up. Secondary efficacy endpoints
included the percentage of patients in remission (very good partial response [VGPR] or com-
plete response [CR]), overall response, toxicity, and progression-free survival 2 (PFS2), defined
as the time from randomisation to the date of second progressive disease, start of third anti-
myeloma treatment, or death from any cause.
The therapeutic efficacy was evaluated in the molecular risk subgroups of standard risk,
high risk (defined as 1 adverse molecular abnormality), and ultra-high risk (2 or more adverse
molecular abnormalities) and was pre-specified by protocol. Adverse molecular abnormalities
were defined as gain(1q), del(17p), t(4;14), t(14;16), or t(14;20). Molecular risk profiling for
the majority of patients (339/383) was performed centrally using multiplex ligation-dependent
probe amplification (MLPA) and quantitative real-time PCR (qRT-PCR) on DNA/RNA
extracted from CD138-selected plasma cells from bone marrow biopsies of patients taken
prior to treatment commencing. In this approach, qRT-PCR is used to assay the expression of
translocation gene partners including t(4;14) MMSET and FGFR3, t(14;16) MAF, and t(14;20)
MAFB. MLPA was used to assay copy number by including probesets at sites of the commonly
deleted and amplified regions in myeloma, e.g., at genes CKS1B on 1q21.3 and TP53 on 17p13.
These techniques have been previously validated and provide equivalent results to interphase
fluorescence in situ hybridisation (iFISH) [11–13]. For the remaining patients (44/383), local
cytogenetic (FISH) reports were centrally reviewed, and only those with a valid result for all
risk markers were included in this analysis.
The presence of minimal residual disease (MRD) was assessed using a validated flow cytom-
etry assay (sensitivity� 0.004%, cutoff 4 × 10−5 bone marrow leucocytes) performed at a single
central laboratory on bone marrow aspirates obtained at the end of initial induction and at 100
days after ASCT. A minimum of 500,000 cells were evaluated with 8-color antibody combina-
tions including CD138, CD38, CD45, CD19, CD56, CD27, CD81, and CD117.
Paraprotein (Sebia, France) and serum free light chains (Freelite, The Binding Site, Bir-
mingham, UK) were assessed at least every 2 months for the first 2 years and then at least every
3 months until disease progression. Urine light chain excretion (Sebia, France) was assessed to
confirm CR. Response and progressive disease were assessed on the basis of IMWG uniform
response criteria [14,15] and reviewed centrally by an expert panel masked to treatment alloca-
tion. Adverse events were graded according to the US National Cancer Institute Common Ter-
minology Criteria for Adverse Events (NCI CTCAE), version 4.0. Adverse reactions were
assessed at the start of each treatment cycle. Serious adverse events (SAEs) were reported for
all patients from the date of randomisation until 30 days after the date of disease progression
except in the case of serious adverse reactions or second primary malignancies, which were
collected for the duration of the trial.
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Statistical analysis
The primary analysis was performed in the intention-to-treat population, which included
all patients who underwent randomisation. The safety population included all patients who
received at least 1 dose of the trial treatment. The primary analysis was designed to compare
KRdc to the triplet control group, which consisted of patients randomised to receive either
Rdc or Tdc. Exploratory analysis was specified to compare KRdc with whichever of the trip-
lets was superior. The primary endpoint of PFS was compared between the treatment
groups with the use of a Cox regression model adjusting for the stratification factors. The
adjusted treatment effect (hazard ratio) and corresponding 95% confidence interval were
estimated with the use of this model. Other time-to-event efficacy endpoints were analysed
similarly. The proportional hazards assumption was assessed informally by plotting the haz-
ards over time (i.e., the log cumulative hazard plot) for each treatment group, and formally
using the simulation-based method of Lin et al. [16]. Subgroup analysis was pre-specified
for the presence or absence of individual adverse cytogenetic abnormalities and cytogenetic
risk status. We did a likelihood ratio test for heterogeneity of treatment effect using Cox
models identical to those used for the main analysis, with the inclusion of terms for the sub-
group in question and the appropriate interaction term. The reported test for heterogeneity
for subgroup analysis corresponds to a 1-degree-of-freedom test for 2 category subgroups
and a 2-degrees-of-freedom test for 3 category subgroups. Continuous variables were sum-
marised with the use of descriptive statistics, and categorical variables were summarised as
numbers and percentages. Time-to-event variables were summarised with the use of the
Kaplan–Meier method. We analysed binary endpoints using a logistic regression model
adjusting for the stratification factors.
Of 2 planned interim analyses, the first, reported here, evaluated PFS when at least 50%
of participants had experienced progressive disease or death. To ensure that an overall sig-
nificance level of 5% was maintained, we used the O’Brien and Fleming alpha-spending
function [17] (interim analysis bound 0.5%, final analysis bound 4.7%). The bound for the
interim analysis was advisory, with the decision to release results at the recommendation of
the Independent Myeloma XI/+ Data Monitoring and Ethics Committee (DMEC) and the
Independent Myeloma XI/+ Trial Steering Committee (TSC). The interim analysis was
done and presented to the DMEC on 12 June 2018. The DMEC recommended to the TSC
that the data be released, and the TSC ratified this decision on 21 June 2018. The final PFS
analysis is planned when 703 progression or death events have been reported, and the final
OS analysis when 466 deaths have been reported. We estimated that a sample size of 1,044
patients would provide the trial with 80% power to detect a risk of disease progression or
death that was 19% lower, and also 80% power to detect a risk of death that was 23% lower,
with KRdc compared to the triplet control group. This is under the assumption of exponen-
tial survival times, with 2 years of recruitment and 4 years of follow-up, at a 2-sided alpha
level of 0.05. All reported p-values are 2-sided and considered significant at an overall sig-
nificance level of 5%.
Ethics statement
The study was approved by the national ethics review board (National Research Ethics Service,
London, UK), the institutional review boards of the participating centres, and the competent
regulatory authority (Medicines and Healthcare Products Regulatory Agency, London, UK),
and was undertaken according to the Declaration of Helsinki and the principles of Good Clini-
cal Practice as espoused in the UK Medicines for Human Use (Clinical Trials) Regulations
2004. All patients provided written informed consent.
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Results
Patients were enrolled between December 2013 and April 2016 at 88 sites in the UK. Overall,
1,056 patients underwent induction randomisation (Fig 1): 526 were allocated to KRdc and
530 to the control group (265 to Rdc and 265 to Tdc). The median follow-up for this analysis is
34.5 months (IQR 27.9 to 41.3), and at the time of analysis all patients had completed their
induction therapy. The groups were well matched across baseline variables, with median age
61 years (range 33–75) (Table 1).
Efficacy
Disease progression or death occurred in 411 patients (171 of 526 patients [32.5%; 101/526,
19.2%, progression and 70/526, 13.3%, death] in the KRdc group and 240 of 530 patients
[45.3%; 151/530, 28.5%, progression and 89/530, 16.8%, death] in the control group). The
median PFS is not yet estimable in the KRdc group, compared to a median of 36.2 months in
the control group. The hazard ratio for disease progression or death was 0.63 (95% CI 0.51 to
0.76, p< 0.001), corresponding to a 37% lower risk in the KRdc group (Fig 2A). There was no
evidence of violation of the assumption of proportional hazards on inspection or using the
method of Lin et al. (p = 0.379). The proportion of patients with 3-year PFS estimated by the
Kaplan–Meier method was 64.5% (95% CI 59.9% to 69.1%) in the KRdc group and 50.3%
(95% CI 45.4% to 55.3%) in the control group.
The improvement in PFS was seen across all subgroups defined by baseline characteristics,
with no significant heterogeneity detected except with respect to age (Fig 2B). For transplant-
eligible patients of all ages, KRdc was associated with significantly prolonged PFS compared to
the control group, but those aged over 65 appeared to benefit to a greater extent, with a hazard
ratio of 0.45 (95% CI 0.31 to 0.65) compared to those 65 or under, where a hazard ratio of 0.70
(95% CI 0.55 to 0.90) was seen (phet = 0.035). Improved PFS was seen in all molecular risk
groups, with no significant heterogeneity between groups (standard risk: hazard ratio 0.62,
95% CI 0.39 to 0.98, median PFS KRdc not estimable [NR] versus control 37 months; high
risk: 0.68, 95% CI 0.40 to 1.14, median PFS KRdc NR versus control 37 months; ultra-high
risk: 0.50, 95% CI 0.20 to 1.25, median PFS KRdc 36 months versus control 20 months; phet =
0.7841) (Fig 2B and Fig A in S1 Text). The results were consistent within each of the groups
with the individual risk lesions t(4;14) and del(17p) (Fig 2B and Fig B in S1 Text). An explor-
atory analysis to compare all 3 induction regimens demonstrates prolonged PFS associated
with KRdc compared to both Rdc and Tdc induction when analysed separately (Fig 2C).
Deeper response rates were seen at the end of induction in patients treated with KRdc com-
pared to the control group, with an odds ratio for achieving at least VGPR of 4.35 (95% CI
3.19–5.94, p< 0.001). At the end of induction, 82.3% of patients in the KRdc group achieved
VGPR or better compared to 58.9% in the control group (Table 2). A higher proportion of
patients in the KRdc group (74.9%) were able to undergo ASCT compared to those in the con-
trol group (63.8%). Post-ASCT VGPR or better was achieved in 91.9% of patients in the KRdc
group compared to 79.3% in the control group.
At the end of induction, MRD negativity (MRD−) was achieved in more patients in the
KRdc group (55% [90/164]) than in the control group (17% [26/157]; 11% [8/74] with Tdc,
22% [18/83] with Rdc). PFS for MRD− patients was improved compared to MRD+ patients
(percent PFS at 3 years from MRD assessment, MRD− 78.7% versus MRD+ 51.9%). Interest-
ingly, there were differences in outcome within the MRD− group, with patients receiving
KRdc doing better (percent PFS at 3 years from MRD assessment, KRdc MRD− 81.8% versus
control MRD− 68.1% [Tdc 62.5% and Rdc 70.6%]). In the MRD+ group the outcomes were
similar (percent PFS at 3 years from MRD assessment, KRdc MRD+ 49.9% versus control
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Table 1. Baseline characteristics.







Median age (range)—years 61 (33 to 75) 62 (36 to 74) 62 (36 to 74) 61 (38 to 74)
Age group—n (%)
�65 years 385 (73.2%) 370 (69.8%) 179 (67.5%) 191 (72.1%)
>65 years 141 (26.8%) 160 (30.2%) 86 (32.5%) 74 (27.9%)
>70 years 12 (2.3%) 24 (4.5%) 12 (4.5%) 12 (4.5%)
Sex—n (%)
Male 317 (60.3%) 326 (61.5%) 170 (64.2%) 156 (58.9%)
Female 209 (39.7%) 204 (38.5%) 95 (35.8%) 109 (41.1%)
Ethnicity—n (%)
White 494 (93.9%) 482 (90.9%) 243 (91.7%) 239 (90.2%)
Black (Black Caribbean, Black African, other) 9 (1.7%) 6 (1.1%) 5 (1.9) 1 (0.4%)
Asian (Indian, Pakistani, Bangladeshi, other) 9 (1.7%) 17 (3.2%) 7 (2.6%) 10 (3.87%)
Other 8 (1.5%) 2 (0.4%) 1 (0.4%) 1 (0.4%)
Unknown 6 (1.1%) 23 (4.3%) 9 (3.4%) 14 (5.3%)
WHO performance status—n (%)
0 225 (42.8%) 224 (42.3%) 101 (38.1%) 123 (46.4%)
1 194 (36.9%) 182 (34.3%) 98 (37.0%) 86 (32.5%)
2 58 (11.0%) 63 (11.9%) 30 (11.3%) 33 (12.5%)
3 20 (3.8%) 26 (4.9%) 17 (6.4%) 9 (3.4%)
4 1 (0.2%) 2 (0.4%) 1 (0.4%) 1 (0.4%)
Unknown 28 (5.3%) 31 (5.8%) 18 (6.8%) 13 (4.9%)
ISS stage—n (%)
I 167 (31.7%) 164 (30.9%) 80 (30.2%) 84 (31.7%)
II 198 (37.6%) 194 (36.6%) 95 (35.8%) 99 (37.4%)
III 117 (22.2%) 122 (23.0%) 63 (23.8%) 59 (22.3%)
Unknown 44 (8.4%) 50 (9.4%) 27 (10.2%) 23 (8.7%)
Immunoglobulin subtype—n (%)
IgG 299 (56.8) 345 (65.1%) 173 (65.3%) 172 (64.9%)
IgA 131 (24.9%) 108 (20.4%) 49 (18.5%) 59 (22.3%)
IgM 4 (0.8%) 3 (0.6%) 1 (0.4%) 2 (0.8%)
IgD 5 (1.0%) 4 (0.8%) 2 (0.8%) 2 (0.8%)
Light chain only 81 (15.4%) 66 (12.5%) 38 (14.3%) 28 (10.6%)
Non-secretor 4 (0.8%) 4 (0.8%) 2 (0.8%) 2 (0.8%)
Unknown 2 (0.4%) 0 0 0
Median creatinine (range)—μmol/l 82 (40 to 395) 81 (30 to 649) 82 (36 to 446) 80 (30 to 649)
Unknown—n (%) 2 (0.4%) 2 (0.4%) 1 (0.4%) 1 (0.4%)
Median LDH (range)—IU/l 248 (83 to 1,510) 257 (2 to 1,477) 257 (5 to 1,477) 256 (2 to 774)
Unknown—n (%) 113 (21.5%) 125 (23.6%) 66 (24.9%) 59 (22.3%)
Molecular risk assessment available—n (%) 204 (38.8%) 179 (33.8%) 85 (32.1%) 94 (35.5%)
Molecular risk—n (% of those available)
Standard 101 (49.5%) 103 (57.5%) 47 (55.3%) 56 (59.6%)
High risk† 81 (39.7%) 60 (33.5%) 31 (36.5%) 29 (30.9%)
Ultra-high risk† 22 (10.8%) 16 (8.9%) 7 (8.2%) 9 (9.6%)
Molecular risk lesions—n (% of those available)
t(4;14) 28 (13.7%) 22 (11.2%) 11 (12.9%) 11 (11.7%)
(Continued)
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MRD+ 52.8% [Tdc 61.8% and Rdc 40.7%]). At 100 days after ASCT, the rate of MRD− had
improved in all groups, but remained higher in the KRdc group (75% [152/202]) than in the
control group (50% [80/160]; 51% [40/79] with Tdc, 49% [40/81] with Rdc). The achievement
of MRD− status after ASCT was also associated with improved outcomes.
OS data were immature at the time of analysis, with follow-up continuing. Data for PFS2, a
key secondary endpoint, showed a significantly improved outcome for patients receiving
KRdc. Second disease progression or death had occurred in 191 patients (85 of 526 patients
[16.2%] in the KRdc group and 106 of 530 patients [20.0%] in the control group). The propor-
tion of patients with 3-year PFS2 was 81.8% (95% CI 78.0% to 85.6%) in the KRdc group com-
pared to 75.1% (95% CI 70.7% to 79.6%) in the control group. (Fig 3A). The hazard ratio for
disease progression or death was 0.75 (95% CI 0.56 to 0.99, p = 0.0451), corresponding to a
25% lower risk in the KRdc group compared to the Tdc/Rdc control group. An exploratory
analysis to compare all 3 induction regimens demonstrates prolonged PFS2 associated with
KRdc compared to Tdc but not Rdc, when analysed separately (Fig 3B).
Safety
Induction treatment was planned for a minimum of 4 cycles and to continue to maximum
response. The median number of treatment cycles received was 4 (range 1 to 12) in the KRdc
group and 6 (1 to 15) in the control group (Rdc median 5, Tdc median 6). The use of a dose
modification schedule in the event of adverse events allowed the vast majority of patients to
complete at least 4 cycles of induction therapy. Patients not completing 4 cycles numbered 50
(9.5%) in the KRdc group and 43 (8.1%) in the Tdc/Rdc control group (Rdc 20, Tdc 23). The
most common reasons cited for stopping induction therapy early were clinician choice (KRdc
22 patients, Tdc/Rdc control 26 patients [Rdc 12, Tdc 14]) or unacceptable toxicity (KRdc 20
patients, Tdc/Rdc control 14 patients [Rdc 4, Tdc 11]); more than 1 reason could be cited per
withdrawal. Overall, the majority of patients stopped induction therapy because they had
reached maximum response as per protocol. For patients completing 4 or more cycles, maxi-
mum response was cited as the reason for stopping in 430/526 (81.7%) in the KRdc group and
413/530 (77.9%) in the Tdc/Rdc control group (Rdc 216, Tdc 197). Clinician choice was cited
in 37/526 (7.0%) in the KRdc group and 61/530 (11.5%) in the Tdc/Rdc control group (Rdc 24,
Tdc 37). Unacceptable toxicity was cited in 25/526 (4.8%) in the KRdc group and 26/530
(4.9%) in the Tdc/Rdc control group (Rdc 7, Tdc 19).
Adverse reactions of any grade that were reported in more than 10% of patients in any
treatment group, grade 3–4 reactions reported in more than 5% of patients in any treatment
Table 1. (Continued)







t(14;16) 7 (3.4%) 0 (0%) 0 (0%) 0 (0%)
t(14;20) 2 (1.0%) 0 (0%) 0 (0%) 0 (0%)
del(17p) 17 (8.3%) 11 (6.1%) 4 (4.7%) 7 (7.4%)
gain(1q) 71 (34.8%) 60 (33.5%) 30 (35.3%) 30 (31.9%)
†High-risk molecular abnormalities were defined as gain(1q), t(4;14), t(14;16), t(14;20), and del(17p). Ultra-high risk was defined as the presence of more than 1 high-
risk lesion.
ISS, International Staging System; KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; LDH, lactate dehydrogenase; Rdc, lenalidomide,
dexamethasone, and cyclophosphamide; Tdc, thalidomide, dexamethasone, and cyclophosphamide.
https://doi.org/10.1371/journal.pmed.1003454.t001
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Fig 2. Progression-free survival. (A) Progression-free survival for KRdc compared to the Tdc/Rdc control group. (B)
Subgroup analysis of progression-free survival with KRdc compared to the Tdc/Rdc control group. �Performed only
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group, and all grade 5 reactions are shown in Table 3. The most common adverse reactions
were haematological. Grade 3 or 4 neutropenia occurred in 16.4% KRdc, 22.3% Rdc, and
12.8% Tdc patients; anaemia in 10.2% KRdc, 5.8% Rdc, and 4.7% Tdc patients; and thrombo-
cytopenia in 8.4% KRdc, 2.3% Rdc, and 1.2% Tdc patients. There was no apparent increase in
for patients with subgroup data available. (C) Progression-free survival for KRdc compared to the Tdc and Rdc groups
separately. HiR, high risk; ISS, International Staging System; KRdc, carfilzomib, lenalidomide, dexamethasone, and
cyclophosphamide; NE, not estimable; P. (het), p-value from likelihood ratio test for heterogeneity of effect; Rdc,
lenalidomide, dexamethasone, and cyclophosphamide; SR, standard risk; Tdc, thalidomide, dexamethasone, and
cyclophosphamide; UHiR, ultra-high risk.
https://doi.org/10.1371/journal.pmed.1003454.g002
Table 2. Response rates.
Timepoint and response Primary comparison Rdc Tdc
KRdc Control (Tdc/Rdc)
At end of initial induction n = 526 n = 530 n = 265 n = 265
CR 93 (17.7%) 37 (7.0%) 19 (7.1%) 18 (6.8%)
nCR 203 (38.6) 142 (26.8%) 90 (34.0) 52 (19.6%)
VGPR 137 (26.0%) 133 (25.1%) 63 (23.8%) 70 (26.4%)
�VGPR 433 (82.3%) 312 (58.9%) 172 (64.9%) 140 (52.8%)
PR 43 (8.2%) 154 (29.1%) 66 (24.9%) 88 (33.2%)
MR 3 (0.6%) 18 (3.4%) 7 (2.6%) 11 (4.2%)
SD 1 (0.2%) 3 (0.6%) 0 (0.0%) 3 (1.1%)
PD 6 (1.1%) 12 (2.3%) 5 (1.9%) 7 (2.6%)
Early death� 6 (1.1%) 5 (0.9%) 2 (0.8%) 3 (1.1%)
Missing 34 (6.7%) 26 (4.9%) 13 (4.9%) 13 (4.9%)
At 100 days post-ASCT$ n = 394 n = 338 n = 179 n = 159
CR 122 (31.0%) 81 (24.0%) 41 (22.9%) 40 (25.2%)
nCR 152 (38.6%) 107 (31.7%) 60 (33.5%) 47 (29.6%)
VGPR 88 (22.3%) 80 (23.7%) 46 (25.7%) 34 (21.4%)
�VGPR 362 (91.9%) 268 (79.3%) 147 (82.1%) 121 (76.1%)
PR 23 (5.8%) 54 (16.0%) 26 (14.5%) 28 (17.9%)
MR 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
SD 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
PD 2 (0.5%) 6 (1.8%) 4 (2.2%) 2 (1.3%)
Early death# 1 (0.3%) 1 (0.6%) 0 (0.0%) 1 (0.6%)
Missing 6 (1.5%) 9 (2.7%) 2 (1.1%) 7 (4.4%)
MRD-negative status
At end of initial induction n = 164 n = 157 n = 83 n = 74
MRD negative 90 (54.9%) 20 (12.7%) 18 (21.7%) 8 (10.8%)
At day 100 after ASCT n = 202 n = 160 n = 79 n = 81
MRD negative 152 (75.2%) 80 (50.0%) 40 (50.6%) 40 (49.4%)
Data given as n (percent).
�All-cause death within 60 days of randomisation.
$Reported of these undergoing ASCT.
#All-cause death within 100 days of high-dose melphalan dose.
ASCT, autologous stem cell transplantation; CR, complete response; KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; MR, minimal response;
MRD, minimal residual disease; nCR, complete response without bone marrow confirmation; PD, progressive disease; PR, partial response; SD, stable disease; Rdc,
lenalidomide, dexamethasone, and cyclophosphamide; Tdc, thalidomide, dexamethasone, and cyclophosphamide; VGPR, very good partial response.
https://doi.org/10.1371/journal.pmed.1003454.t002
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peripheral sensory neuropathy from the addition of carfilzomib to Rdc. Grade 5 adverse events
were reported during induction in 3 patients receiving KRdc and 4 patients receiving Tdc/Rdc
control treatment. Thromboembolic events occurred at slightly higher rates in patients
Fig 3. Progression-free survival 2. (A) Progression-free survival 2 for the KRdc group compared to the Tdc/Rdc
control group. Note that medians and confidence intervals were inestimable. (B) Progression-free survival 2 for the
KRdc group compared to the Tdc and Rdc control groups separately. Note that medians and confidence intervals were
inestimable. KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; Rdc, lenalidomide,
dexamethasone, and cyclophosphamide; Tdc, thalidomide, dexamethasone, and cyclophosphamide.
https://doi.org/10.1371/journal.pmed.1003454.g003
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receiving KRdc compared to Rdc. Thromboembolic events within the study have been exam-
ined in more detail in another paper [18]. The incidence of SAEs was 69.5% in those receiving
KRdc and 55.3% in those receiving Tdc/Rdc control treatment. The majority of SAEs in all
groups were due to infections or infestations.
Cardiac events were closely examined (Table 3). Grade 3 or 4 cardiac failure was reported
in 4 patients (0.8%) in the KRdc group and no patients in the Tdc/Rdc control group, and pul-
monary oedema in 2 (0.4%) patients in the KRdc group and no patients in the triplet control
group. Grade 3 or 4 hypertension was reported in 2 patients (0.4%) in the KRdc group and 1
patient (0.2%) in the Tdc/Rdc control group.
Exploratory analysis using optimal risk-adapted control group
To address whether the improvement in outcome with KRdc identified was attributable to the
efficacy of the combination or was influenced by the control group that could, in the current
treatment landscape, be considered suboptimal, we explored data from the risk-adapted ran-
domisation step of the trial. Patients who achieved a suboptimal response (minimal or partial
response) to triplet Tdc/Rdc induction were randomised between sequential triplet therapy
with a proteasome inhibitor (CVD) or no further therapy prior to transplant. We have previ-
ously reported that CVD intensification was associated with improved outcome [9]. In order
to remove this potential bias from the current analysis, we compared outcomes excluding
those patients in the triplet control group who had achieved a partial or minimal response to
initial induction and been randomised to the suboptimal approach of no further therapy prior
to transplant. Results remained consistent with the intention-to-treat comparison (Fig C in S1
Text). The hazard ratio for the risk of progression or death was 0.64 (95% CI 0.52 to 0.78, p<
0.001), corresponding to a 36% lower risk in the KRdc group compared to the optimal risk-
adapted control group.
Discussion
This is a large phase III study of a lenalidomide and carfilzomib combination regimen for
newly diagnosed myeloma, with the results highlighting the efficacy and safety of this combi-
nation in previously untreated patients, supporting prior early phase studies [19,20]. The use
of KRdc in this setting is associated with a significant improvement in PFS in comparison to a
combination comprising either Tdc or Rdc, reducing the risk of progression or death by 37%.
Recipients of KRdc induction were 4.35 times more likely to achieve at least a VGPR after a
median of only 4 cycles of therapy, highlighting the rapidity of disease control. Responses of at
least CR without bone marrow confirmation were seen in 56% with KRdc versus 34% with
Tdc/Rdc pre-transplant, and 70% and 56% post-transplant, respectively, consistent with the
benefit of the KRdc combination. Around 30% of cases had material available for assessment
of MRD status; post-ASCT high rates of MRD negativity were attained, and importantly MRD
− was associated with significantly longer PFS. This pattern of results, with a slightly higher
rate of MRD− than of CR, is typical of myeloma studies reported recently; for example, IFM-
2009 [21] reported CR rates of 59% and MRD− rates of 79% following ASCT. These differ-
ences reflect both the half-life of immunoglobulins and the availability of bone marrow confir-
mation of CR, a requirement of the definition.
Even within the group of patients achieving MRD negativity at a level of sensitivity of
0.004% (cutoff 4 × 10−5 bone marrow leucocytes), there were differences in outcome, with the
KRdc-treated group having significantly better PFS compared to those receiving Tdc/Rdc trip-
lets. The cause for this difference is unknown, but we postulate there were deeper responses in
the KRdc-treated group compared to the control group that translated to improved PFS.
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Table 3. Adverse reactions.
Adverse reaction KRdc (n = 511) Rdc (n = 257) Tdc (n = 261)






1 (0.2%) 0 185
(70.9%)

























0 80 (30.7%) 6 (2.3%) 0 0 35 (13.6%) 3 (1.2%) 0 0
Infections
Cellulitis 4 (0.8%) 5 (1.0%) 0 1
(0.2%)�
1 (0.4%) 1 (0.4%) 0 0 0 1 (0.4%) 0 0




Sepsis 1 (0.2%) 10 (2.0%) 14
(2.7%)




1 (0.2%) 0 0 114
(43.7%)
2 (0.8%) 0 0 158
(61.5%)
1 (0.4%) 1 (0.4%) 0
Diarrhoea 136
(26.6%)
15 (2.9%) 0 0 64 (24.5%) 4 (1.5%) 0 0 50 (19.5%) 5 (1.9%) 0 0
Nausea 94 (18.4%) 4 (0.8%) 0 0 45 (17.2%) 5 (1.9%) 0 0 65 (25.3%) 1 (0.4%) 0 0
Gastrointestinal—other 3 (0.6%) 2 (0.4%) 0 0 1 (0.4%) 0 0 1
(0.4%)�









0 1 (0.2%) 0 58 (22.2%) 1 (0.4%) 0 0 124
(48.2%)
3 (1.2%) 0 0
Tremor 29 (5.7%) 0 0 0 30 (11.5%) 1 (0.4%) 0 0 58 (22.6%) 0 0 0
Other
Back pain 47 (9.2%) 4 (0.8%) 0 0 41 (15.7%) 2 (0.8%) 0 0 32 (12.5%) 7 (2.7%) 0 0
Cough 53 (10.4%) 7 (1.4%) 0 0 17 (6.5%) 2 (0.8%) 0 0 23 (8.9%) 2 (0.8%) 0 0
Dyspnoea 71 (13.9%) 5 (1.0%) 0 1 (0.2%) 18 (6.9%) 7 (2.7%) 0 0 40 (15.6%) 4 (1.6%) 0 0
Fatigue/lethargy 204
(39.9%)




5 (1.9%) 0 124
(48.2%)
3 (1.2%) 0 0
Fever 85 (16.6%) 26 (5.1%) 0 0 31 (11.9%) 4 (1.5%) 1 (0.4%) 0 23 (8.9%) 9 (3.5%) 1 (0.4%) 0
Oedema limbs 60 (11.7%) 2 (0.4%) 0 0 32 (12.3%) 0 0 0 48 (18.7%) 0 0 0
Pain—other 40 (7.8%) 3 (0.6%) 0 0 26 (10.0%) 3 (1.1%) 0 0 16 (6.2%) 6 (2.3%) 0 0





29 (5.7%) 3 (0.6%) 0 45 (17.2%) 6 (2.3%) 0 0 32 (12.5%) 5 (1.9%) 0 0
ARs of special interest
Infusion reaction 13 (2.5%) 3 (0.6%) 1 (0.2%) 0 4 (1.5%) 0 0 0 2 (0.8%) 0 0 0
Hypotension 21 (4.1%) 2 (0.4%) 3 (0.6%) 0 12 (4.6%) 2 (0.8%) 0 0 13 (5.1%) 2 (0.8%) 0 0
Other thrombosis/
embolism
8 (1.6%) 0 4 (0.8%) 0 1 (0.4%) 1 (0.4%) 0 0 1 (0.4%) 2 (0.8%) 0 0
Deep vein thrombosis 30 (5.9%) 6 (1.2%) 0 0 10 (3.8%) 2 (0.8%) 1 (0.4%) 0 17 (6.6%) 4 (1.6%) 0 0
Heart failure 1 (0.2%) 4 (0.8%) 0 0 0 0 0 0 0 0 0 0
Hypertension 1 (0.2%) 2 (0.4%) 0 0 2 (0.8%) 0 0 0 0 1 (0.4%) 0 0
Pulmonary oedema 2 (0.4%) 2 (0.4%) 0 0 0 0 0 0 0 0 0 0
(Continued)
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We demonstrate that patients with high- and ultra-high-risk disease benefit from the use of
KRdc, with no heterogeneity in the impact of the KRdc combination compared to standard-
risk patients. This finding is encouraging, showing activity in patients with t(4;14) and del
(17p), subgroups in whom there has been a lack of progress over the last decade [22]. Impor-
tantly, exposure to proteasome inhibitor and immunomodulatory agent combinations has
been reported to be beneficial for these subgroups of patients [23], and potentially the greater
activity of carfilzomib compared to bortezomib is associated with these excellent results. The
superiority of carfilzomib compared to bortezomib was demonstrated in patients with relapsed
disease in the ENDEAVOR study [5]. The superiority of carfilzomib is not, however, sup-
ported by data from the recently reported ENDURANCE study [24], which examined the
combination of carfilzomib with lenalidomide and dexamethasone (without cyclophospha-
mide) as induction treatment for newly diagnosed myeloma patients. This study did not iden-
tify a difference in outcome between patients receiving KRd or bortezomib, lenalidomide, and
dexamethasone (VRd), but it was not carried out in the same population as Myeloma XI+,
excluding patients with high-risk disease and those destined for stem cell transplantation. For
transplant-eligible patients of all risk subgroups, the phase II FORTE study [25] has reported
preliminary data suggesting the KRd combination can achieve deeper responses than the com-
bination of carfilzomib, cyclophosphamide, and dexamethasone, but full results are awaited.
An exploratory analysis demonstrated that KRdc was associated with prolonged PFS com-
pared to both Rdc and Tdc when analysed separately. Any comparison between Rdc and Tdc
is not powered within this contemporaneously recruited cohort, but from the preceding Mye-
loma XI trial, Rdc was associated with prolonged PFS, PFS2, and OS compared to Tdc [8].
KRdc was associated with significantly prolonged PFS2 compared to the pre-planned Tdc/Rdc
triplet control group comparator. On exploratory analysis, KRdc was associated with pro-
longed PFS2 compared with Tdc, but not Rdc. However, the follow-up remains immature for
this endpoint, which will be re-examined, along with OS, at final analysis.
The KRdc combination was well tolerated in the present study, with a low incidence of
peripheral neuropathy. Interestingly, there was also less neutropenia in the KRdc group, possi-
bly due to the fewer cycles required to achieve maximum response (median 4 versus 5 cycles)
and the associated rapid, deep responses with improved bone marrow function. In relapsed
patients in the ENDEAVOR study [5,26], grade 3 or higher cardiac failure were seen in 22/462
(4.8%) carfilzomib-treated patients compared to only 8/456 (1.8%) patients in the control
group. In the newly diagnosed myeloma setting investigated here, the overall incidence of car-
diac adverse events was low, which may be related to the different dose of carfilzomib used in
Table 3. (Continued)
Adverse reaction KRdc (n = 511) Rdc (n = 257) Tdc (n = 261)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Myocardial infarction 0 1 (0.2%) 1 (0.2%) 0 0 0 0 0 0 0 0 0
Acute coronary syndrome 1 (0.2%) 0 0 0 0 0 0 0 0 0 0 0
Cardiac disorders—other 0 3 (0.6%) 1 (0.2%) 0 2 (0.8%) 1 (0.4%) 0 0 2 (0.8%) 1 (0.4%) 0 0
The safety population included all patients who received at least 1 dose of the trial treatment. Adverse reactions of any grade that were reported in >10% of patients in
any treatment group, grade 3–5 in >5% of patients in any treatment group, or grade 5 in any treatment group are listed, along with other adverse events of special
interest.
�Patients whose cause of death included “sepsis” in addition to the cause in this row.
AR, adverse reaction; KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; Rdc, lenalidomide, dexamethasone, and cyclophosphamide; Tdc,
thalidomide, dexamethasone, and cyclophosphamide.
https://doi.org/10.1371/journal.pmed.1003454.t003
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our study (36 mg/m2 versus 56 mg/m2) or the absence of the impact of prior therapy. The
exclusion of patients with a significant history of cardiac disease was at the discretion of the
investigators and so may have affected this finding. The treatment was delivered in community
as well as academic hospitals, with no significant difficulties encountered.
A potential criticism of the Myeloma XI+ study relates to the control arm, where a triplet
combination that was a standard of care in prior UK trials and that is in widespread use across
the world was used. A comparison of a different immunomodulatory drug and proteasome
inhibitor combination (e.g., VRd or bortezomib, thalidomide, and dexamethasone) would also
have been of interest because of more recent uptake of such combinations in the EU and US,
but this was not the position when the study was initially implemented. Despite this, the out-
come for the control arm in this study compares well to other combinations, with a median
PFS of 36.2 months. In the IFM 2009 study [21], VRd was associated with a median PFS of 36
versus 50 months for those who underwent ASCT. In the IFM study all patients received lena-
lidomide maintenance, in contrast to patients in the Myeloma XI+ study, where only 50%
received maintenance. In real-world data reported from the Mayo Clinic [27], which included
243 patients who received VRd followed by ASCT, half of whom received maintenance ther-
apy, VRd was associated with a median PFS of 28 months. To further address this question we
utilised data from the current trial, where an immunomodulatory-agent triplet was used ini-
tially followed by a proteasome triplet for suboptimal responders not achieving at least a
VGPR. Using these data we were able to generate optimised outcome data, but even in com-
parison to this, the use of KRdc was associated with significantly improved outcomes. Another
limitation includes the unblinded nature of the therapy randomisation; both the patient and
local investigator were aware of the treatment being delivered.
In conclusion, in transplant-eligible, newly diagnosed multiple myeloma patients in the
Myeloma XI+ study, a carfilzomib and lenalidomide combination, KRdc, was well tolerated
and was associated with an increased percentage of patients achieving at least a VGPR, more
MRD-negative responses, and significantly prolonged PFS compared to a immunomodula-
tory-agent-based triplet induction combination.
Supporting information
S1 Text. Fig A—Progression-free survival by cytogenetic risk. Progression-free survival (PFS)
for carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) compared to
the triplet control group (Rdc/Tdc) within each cytogenetic risk group. (A) Standard risk, (B)
high risk, (C) ultra-high risk. Adverse molecular abnormalities were defined as gain(1q), del
(17p), t(4;14), t(14;16), or t(14;20). Efficacy in the subgroups of standard risk, high risk
(defined as 1 adverse cytogenetic abnormality) and ultra-high risk (2 or more adverse cyto-
genetic abnormalities) were pre-specified by protocol. CI, confidence interval; HR, hazard
ratio; m, months. Fig B—Progression-free survival for patients with/without t(4;14) and del
(17p). Progression-free survival (PFS) for carfilzomib, lenalidomide, dexamethasone, and
cyclophosphamide (KRdc) compared to the triplet control group (Rdc/Tdc) for patients with
the cytogenetic lesions t(4;14) and del(17p). (A) t(4;14), (B) no t(4;14), (C) del(17p), (D) no del
(17p). CI, confidence interval; HR, hazard ratio; m, months. Fig C—Progression-free survival
adjusted for CVD randomisation. Progression-free survival (PFS) for carfilzomib, lenalido-
mide, dexamethasone, and cyclophosphamide (KRdc) compared to the triplet control group
(Rdc/Tdc) with patients achieving a suboptimal response to triplet treatment and randomised
to no intensification therapy removed. CI, confidence interval; HR, hazard ratio; m, months.
Table A—Myeloma XI+ study sites and principal investigators. Text A—CONSORT Checklist.
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